Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
Portfolio Pulse from Vandana Singh
Takeda Pharmaceutical's dengue vaccine, Qdenga (TAK-003), has received WHO prequalification, making it eligible for UN procurement. This approval follows its acceptance in several countries and regions. The vaccine is recommended for children aged 6-16 in high dengue burden areas. Takeda plans to produce 100 million doses annually by 2030 in partnership with Biological E. Limited. Sanofi's CYD-TDV is also prequalified by WHO.
May 15, 2024 | 6:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sanofi's CYD-TDV dengue vaccine is also prequalified by WHO, indicating its continued relevance in the dengue vaccine market. However, the focus on Takeda's new approval may overshadow Sanofi's existing product.
While Sanofi's CYD-TDV is already prequalified, the news primarily highlights Takeda's new approval. This may not significantly impact Sanofi's stock in the short term, but it underscores the competitive landscape.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Takeda's dengue vaccine Qdenga (TAK-003) has received WHO prequalification, making it eligible for UN procurement. This is a significant milestone for Takeda, potentially boosting its market presence and revenue in dengue-endemic regions.
The WHO prequalification allows Takeda's vaccine to be procured by UN agencies, significantly expanding its market reach. This approval is likely to positively impact Takeda's stock in the short term due to increased revenue potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100